Loading the records…
Loading the records…
S.494, the National Plan for Epilepsy Act, is an early-stage coordination bill with zero authorized spending. It creates an advisory council and mandates federal research coordination for epilepsy but appropriates no funds. Market impact is negligible — no direct revenue driver for any public company.
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
There are no material market implications from S.494 in its current form. The bill authorizes no funding and alters no commercial incentives. UCB S.A. (OTC: $UCBJY) has the most structural exposure to epilepsy drug development, but this bill does not change its revenue outlook. Broader pharma (PFE, LLY, ABBV, VRTX) are unaffected. The provided market data shows $PFE at $26.71 (30-day -4.91%), $LLY at $920.60 (30-day +0.09%), $ABBV at $213.05 (30-day -2.05%), and $VRTX at $428.21 (30-day -4.1%) — these moves are driven by company-specific factors and broader market dynamics, not by this bill.
S.494 was introduced on February 10, 2025, in the 119th Congress by Sen. Schmitt (R-MO) and has 19 cosponsors. It was referred to the Senate HELP Committee. The bill requires HHS to establish a National Plan for Epilepsy and an advisory council, coordinating research and services across federal agencies. Critically, the bill authorizes zero dollars in spending — it is a policy-and-coordination-only bill. An identical companion bill (HR1189) has been introduced in the House but likewise remains in committee.
The money trail is straightforward: there is no money. Authorization without appropriation means no new federal grants, contracts, or procurement commitments flow to any private company. The bill's provisions sunset on December 31, 2035, but without any funding mechanism, the plan exists only as a reporting and coordination framework.
Structural winners and losers: UCB remains the most directly exposed U.S.-traded pure-play in epilepsy, with Briviact and Vimpat generating significant revenue. However, the bill does nothing to change prescribing patterns, pricing, or patient access. Broader CNS pharma players like Vertex (exondysio? no — VX-548 for pain, not epilepsy), Pfizer, Eli Lilly, and AbbVie have CNS divisions but no direct epilepsy product exposure comparable to UCB. The bill's coordination may eventually streamline research, but that is years out and contingent on future appropriations.
Real market data shows UCB (United Community Banks — a bank, NOT the Belgian pharma UCB) is miscoded in the provided data. The ticker in the provided data belongs to United Community Banks (a regional bank), not UCB S.A. (the Belgian pharma), which does not trade on U.S. exchanges as . The Belgian pharma UCB trades OTC as $UCBJY. This creates a significant analytical limitation: the pure-play epilepsy company is not directly captured in the provided market data.
Timeline: The bill is in the earliest legislative stage. It must pass committee, pass both chambers in identical form, and be signed by the President. Given no funding and no controversy, passage probability is moderate but distant. Any market impact requires at minimum a separate appropriations bill, which has not been introduced.
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
Multiple independent sources confirm this signal’s market thesis
Matched on shared policy language across AI analyses, with ticker & timing weight
MERCK SHARP & DOHME LLC: $1.8B Department of Health and Human Services Contract Vehicle
OHIO DEPARTMENT OF MEDICAID: $28.2B Department of Health and Human Services Grant
MULTIPLE RECIPIENTS: $1.2B Department of Health and Human Services Federal Award
MULTIPLE RECIPIENTS: $2.1B Department of Health and Human Services Federal Award
MULTIPLE RECIPIENTS: $4.6B Department of Health and Human Services Federal Award
MULTIPLE RECIPIENTS: $4.6B Department of Health and Human Services Federal Award
MULTIPLE RECIPIENTS: $4.0B Department of Health and Human Services Federal Award
MULTIPLE RECIPIENTS: $1.4B Department of Health and Human Services Federal Award
Executive orders & memoranda affecting the same sectors or companies
This executive order establishes a Women's Health Division within the NIH to coordinate and accelerate research on understudied women's health conditions, and creates a White House Women's Health Task Force to drive policy reforms and translation of research into clinical practice across federal agencies. It directs specific agencies to prioritize research, data collection, and translation into prevention, diagnosis, and treatment, with a focus on all life stages from infancy through aging.
This executive order directs the Secretaries of State, Labor, and Homeland Security to coordinate with Commerce, Education, and the SBA when processing H-1B petitions, and requires them to consider whether the employer has engaged in layoffs of similarly situated U.S. workers within the past year. It also orders the Labor Department to review past labor condition applications for potential enforcement actions against sponsoring employers, effectively tightening scrutiny on H-1B usage, especially by outsourcing firms.
This proclamation orders the Secretaries of War and Veterans Affairs to mandate rapid, ongoing digital sharing of military personnel and medical records, deploy AI-powered tools for benefits applications, and update existing IT contracts for interoperability. It also requires the Transition Assistance Program to connect separating service members to specific jobs or training programs before discharge.
Free — no credit card
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →